The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

QUOTES-U.S. backs giving poorer countries access to COVID-19 vaccine patents, reversing stance

Thu, 06th May 2021 10:30

(Adds material)

May 6 (Reuters) - U.S. President Joe Biden on Wednesday
supported waiving intellectual property rights for COVID-19
vaccines, bowing to mounting pressure from Democratic lawmakers
and more than 100 other countries, but angering pharmaceutical
companies.

Following are reactions to the latest developments.

GAVI, THE GLOBAL VACCINE ALLIANCE

"We recognise also the significance of the (Biden)
administration’s commitment to work towards increasing raw
material production which will have an immediate impact on
alleviating current global supply constraints.

"Gavi urges now that in the interests of global equitable
access the US supports manufacturers to transfer not only IP but
also know-how in a bid to urgently boost global production."

THE INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS
& ASSOCIATIONS (IFPMA)

"Waiving patents of COVID-19 vaccines will not increase
production nor provide practical solutions needed to battle this
global health crisis. On the contrary, it is likely to lead to
disruption.

"The only way to ensure quick scaling up of and equitable
vaccine access to all those in need remains pragmatic and
constructive dialogue with the private sector."

SOUTH AFRICAN GOVERNMENT

"President (Cyril) Ramaphosa welcomes the position adopted
by the United States as an important reinforcement of a campaign
led by South Africa and India on behalf of emerging economies
that face vaccine shortages and production challenges.

"The anticipated temporary waiver provides a global response
to COVID-19. The proposal establishes a global solution to
enhance manufacturing and boost supply capacity, and enables
coordination and access to information currently under patent
protection.

"For countries that do not currently have manufacturing
capacity on certain medical technologies, the waiver could open
up more supply options and avoid countries being reliant on only
one or two suppliers. Where supply capacity currently exists, it
can be repurposed to COVID vaccine production and in this way
improve the supply available to all nations."

AUSTRALIAN TRADE MINISTER DAN TEHAN

"We welcome this positive development and look forward to
working with the U.S. and others to find solutions that boost
the global rollout of COVID-19 vaccines.

"Close collaboration between governments and vaccine
manufacturers will remain vital."

NEW ZEALAND TRADE MINISTER DAMIEN O'CONNOR

"New Zealand supports the waiver of IP protections on
vaccines as an important part of our collective efforts to
address the human catastrophe of the pandemic.

"We are also working in APEC, the WTO and other fora to
address other elements of vaccine supply issues including
through the supply chains that are limiting the availability of
vaccines regionally and globally."

ITALIAN MINISTRY OF HEALTH ROBERTO SPERANZA

"Biden's breakthrough on free access to vaccine patents for
all is an important step forward. Europe must also play its
part. This pandemic has taught us that we can only win
together."

DOCTORS WITHOUT BORDERS

"It is crucial that the waiver not just apply to
preventative vaccines, but it should also cover other medical
tools for COVID-19, including treatments for people who fall ill
and diagnostics to help curb the spread, as originally proposed
seven months ago.

"While this decision means other manufacturers will have the
information they need from pharmaceutical corporations - and the
legal permission - to help scale up global supply and get more
shots into the arms of people everywhere, this won't happen
immediately.

"For the remaining countries that continue to oppose the WTO
waiver..., they must drop their objections and put people’s
health before pharmaceutical profits, and waive IP on all
COVID-19 medical tools, including vaccines."

OXFAM HEALTH POLICY MANAGER ANNA MARRIOTT

“In this moment of crisis, we applaud the decision of
President Biden and his administration to pursue a new path that
prioritizes public health over private profits.

"This is a testament to the widespread public movement
calling for an end to vaccine monopolies.

“We are at a crucial point in the fight against coronavirus,
yet we have remained essentially at the mercy of a handful of
giant pharmaceutical corporations that have monopoly control
over the life-saving technologies we all need. The UK shouldn't
be left standing on the wrong side of history and must join the
U.S. in doing the right thing for humanity.

“We will now look to the White House for leadership in a
strong WTO outcome, in urgently insisting on the transfer of
technologies through the World Health Organization COVID-19
Technology Access pool, and in investing strategically to build
up regional vaccine hubs to defeat this and future pandemics."

GORDON BROWN, U.N. GLOBAL AMBASSADOR AND FORMER BRITISH
PRIME MINISTER

"I welcome the American decision on temporary patent waiver
which makes the COVID-19 vaccine accessible. Now we must make
the vaccine affordable. No one is safe until everyone is safe
and on June 11, at the G7 meeting, the richest countries should
make the momentous decision to pay two thirds of the $60 billion
cost of vaccinating the world."
(Reporting by Reuters staff; Editing by Nick Macfie and Mark
Heinrich)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.